|
[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.
|
|
[2]BROWNING JD, SZCZEPANIAK LS, DOBBINS R, et al.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J].Hepatology, 2004, 40 (6) :1387-1395.
|
|
[3]SCHWIMMER JB, CELEDON MA, LAVINE JE, et al.Heritability of nonalcoholic fatty liver disease[J].Gastroenterology, 2009, 136 (5) :1585-1592.
|
|
[4]MALHI H, GORES GJ.Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease[J].Semin Liver Dis, 2008, 28 (4) :360-369.
|
|
[5]BOPPIDI H, DARAM SR.Nonalcoholic fatty liver disease:hepatic man-ifestation of obesity and the metabolic syndrome[J].Postgrad Med, 2008, 120 (2) :e1-e7.
|
|
[6]PONIACHIK J, MANCILLA C, CONTRERAS J, et al.Obesity:risk factor for steatohepatitis and hepatic fibrosis[J].Rev Med Chil, 2002, 130 (5) :731-736.
|
|
[7]DUAN XY, FAN JG.Nonalcoholic fatty liver disease (NAFLD) :summary of the 2011 conference of the Asia Pacific Association for the Study of the Liver (APASL) [J].J Clin Hepatol, 2011, 27 (5) :458-461, 470. (in Chinese) 段晓燕, 范建高.2011亚太肝病学会非酒精性脂肪性肝病纪要[J].临床肝胆病杂志, 2011, 27 (5) :458-461, 470.
|
|
[8]BAULANDE S, LASNIER F, LUCAS M, et al.A transmembrane protein corresponding to a novel dietary-and obesity-linked mRNA specifi-cally expressed in the adipose lineage[J].J Biol Chem, 2001, 276 (36) :33336-33344.
|
|
[9]ROMEO S, HUANG-DORAN I, BARONI MG, et al.Unravelling the pathogenesis of fatty liver disease;patatin-like phospholipase domain-containing 3 protein[J].Curr Opin Lipdol, 2010, 21 (3) :247-252.
|
|
[10]ROMEO S, KOZLITINA J, XING C, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2008, 40 (12) :1461-1465.
|
|
[11]LI Q, QU HQ, RENTFRO AR, et al.PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population[J].Clin Invest Med, 2012, 35 (4) :e237-e245.
|
|
[12]REMEO S, SENTINELLI F, DASH S, et al.Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent[J].Int J Obes (Lond) , 2010, 34 (1) :190-194.
|
|
[13]WAGENKNECHT LE, PALMER ND, BOWDEN DW, et al.Association of PNPLA3 with nonalcoholic fatty liver disease in a minority cohort:the insulin Resistance Atherosclerosis Family Study[J].Liver Int, 2011, 31 (3) :412-416.
|
|
[14]HOTTA K, YONEDA M, HYOGO H, et al.Association of the rs738409 polymorphism in PNPLA3 with iver damage and the development of nonalcoholic fatty liver disease[J].BMC Med Genet, 2010, 11:172.
|
|
[15]ZHOU YJ, LI YY, NIE YQ, et al.Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people[J].J Gastroenterol Hepatol, 2010, 25 (4) :772-777.
|
|
[16]LIN YC, CHANG PF, HU FC, et al.A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children[J].J Pediatr, 2011, 158 (5) :740-744.
|
|
[17]LI Y, XING C, TIAN Z, et al.Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population[J].BMC Med Genet, 2012, 13 (1) :113.
|
|
[18]LI Y, XING C, COHEN JC, et al.Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China[J].Hepatology, 2012, 55 (1) :327-328.
|
|
[19]SOOKOIAN S, PIROLA CJ.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease[J].Hepatology, 2011, 53 (6) :1883-1894.
|
|
[20]VELENTI L, AL-SERRI A, DALY AK, et al.Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (4) :1209-1217.
|
|
[21]SPELIOTES EK, YERGES-ARMSTRONG LM, WU J, et al.Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits[J].PLoS Genet, 2011, 7 (3) :e1001324.
|
|
[22]GUICHELAAR M, GAWRIEH S, OLIVIER M, et al.Interactions of allelic variance of PNPLA3 with non genetic factors in predicting NASH and non-hepatic complications of severe obesity[J].Obesity (Silver Spring) , 2013.[Epub ahead of print]
|
|
[23]KANTARTZIS K, PETER A, MACHICAO F, et al.Dissociation between fatty liver and insulin resis tance in humans carrying a variant of the patatin-like phospholipase 3 gene[J].Diabetes, 2009, 58 (11) :2616-2623.
|
|
[24]CHAMOUN Z, VACCA F, PARTON RG, et al.PNPLA3/adiponutrin functions in lipid droplet formation[J].Biol Cell, 2013, 105 (5) :219-233.
|
|
[25]YAO Z.Human Apolipoprotein C-III-A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins[J].Cardiovasc Hematol Disord Drug Targets, 2012, 12 (2) :133-140.
|
|
[26]MILLER M, RHYNE J, CHEN H, et al.APOCIII promoter polymorphisms C–482T and T–455C are associated with the metabolic syndrome Arch[J].Arch Med Res, 2007, 38 (4) :444-451.
|
|
[27]GUETTIER JM, GEORGOPOULOS A, TSAI MY, et al.Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein CIII genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population[J].J Clin Endocrinol Metab, 2005, 90 (3) :1705-1711.
|
|
[28]van DIJK KW, RENSEN PC, VOSHOL PJ, et al.The role and mode of action of apolipoproteins CIII and AV:synergistic actors in triglyceride metabolism?[J].Curr Opin Lipidol, 2004, 15 (3) :239-246.
|
|
[29]ABD-EL-AZIZ TA, MOHAMED RH, EL-SHAL AS.Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease[J].J Cardiovasc Transl Res, 2013, 6 (3) :430-435.
|
|
[30]PETERSEN KF, DUFOUR S, HARIRI A, et al.Apolipoprotein C3gene variants in nonalcoholic fatty liver disease[J].N Engl J Med, 2010, 362 (12) :1082-1089.
|
|
[31]KOZLITINA J, BOERWINKLE E, COHEN JC, et al.Dissociation between APOCIII variants, hepatic triglyceride content and insulin resistance[J].Hepatology, 2011, 53 (2) :467-474.
|
|
[32]SENTINELLI F, ROMEO S, MAGLIO C, et al.Lack of effect of apolipoprotein C3 polymorphisms on in dices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans[J].Lipids Health Dis, 2011, 10 (10) :93.
|
|
[33]VALENTI L, NOBILI V, AL-SERRI A, et al.The APOCIII T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3I148M genotype in patients with nonalcoholic fatty liver[J].J Hepatol, 2011, 55 (6) :1409-1414.
|
|
[34]ROMERO-GMEZ M.APOC3 polymorphisms and non-alcoholic fatty liverdisease:Resolving some doubts and raising others[J].J Hepatol, 2011, 55 (6) :1184-1186.
|
|
[35]OLIVIERI O, MARTINELLI N, SANDRI M, et al.Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and“insulin-resistant”T-455C APOC3 gene polymorphism in heart disease patients:example of gene–diet interaction[J].Clin Chem, 2005, 51 (2) :360-367.
|
|
[36]LI WW, DAMMERMAN MM, SMITH JD, et al.Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyc-eridemia[J].J Clin Invest, 1995, 96 (6) :2601-2605.
|
|
[37]RUSSO GT, MEIGS JB, CUPPLES LA, et al.Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk:the Framingham offspring study[J].Atherosclerosis, 2001, 158 (1) :173-181.
|
DownLoad: